Desjardins Global Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Desjardins Global Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$767K	Sell	873 -482	-36%	-$397K	0.08%	202
2023 Q3	$1.12M	Sell	1,355 -871	-39%	-$685K	0.12%	168
2023 Q2	$1.6M	Sell	2,226 -520	-19%	-$401K	0.18%	131
2023 Q1	$2.26M	Sell	2,746 -1,003	-27%	-$756K	0.28%	70
2022 Q4	$2.7M	Sell	3,749 -1,118	-23%	-$825K	0.43%	39
2022 Q3	$3.35M	Buy	4,867 +11	+0.2%	+$6.92K	0.42%	37
2022 Q2	$2.87M	Sell	4,856 -905	-16%	-$588K	0.38%	57
2022 Q1	$4.02M	Sell	5,761 -3,643	-39%	-$2.3M	0.35%	57
2021 Q4	$5.94M	Buy	+9,404	New	+$5.78M	0.51%	47

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Desjardins Global Asset Management's REGN Position: Q4 2023 in Review

Desjardins Global Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 36% in Q4 2023, selling an estimated $397K and leaving 873 shares worth $767K. The position accounts for 0.08% of the portfolio, ranked #202.

Desjardins Global Asset Management first reported a position in REGN in Q4 2021 and has held it in 9 quarters since. The position peaked at $5.94M in Q4 2021. 1,272 funds tracked by Wall St. Rank hold REGN as of Q4 2023.

Desjardins Global Asset Management held 873 shares of Regeneron Pharmaceuticals worth $767K as of Q4 2023.
Desjardins Global Asset Management sold 482 Regeneron Pharmaceuticals shares in Q4 2023, an estimated $397K.
Regeneron Pharmaceuticals made up 0.08% of Desjardins Global Asset Management's portfolio in Q4 2023, its #202 holding.
Desjardins Global Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 9 quarters since.
Desjardins Global Asset Management's Regeneron Pharmaceuticals position peaked at $5.94M in Q4 2021.
1,272 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2023.

Based on Desjardins Global Asset Management's 13F filing for Q4 2023, filed 30 Jan 2024.